Century Therapeutics vs Sutro Biopharma
Century Therapeutics reported revenue of $109 million in fiscal 2025, about the same as Sutro Biopharma's $102 million in fiscal 2025. Century Therapeutics' revenue grew 1556.8% in its latest year, and Sutro Biopharma's grew 65.2%. Century Therapeutics had an operating margin of -15.8%, against -154.5% at Sutro Biopharma.
Side by side
| Century Therapeutics | Sutro Biopharma | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $109M | $102M |
| Revenue growth | 1,556.8% | 65.2% |
| Revenue growth a year, last 5 years | — | 19.1% |
| Gross margin | — | — |
| Operating margin | −15.8% | −154.5% |
| Net margin | −8.8% | −186.4% |
| Free cash flow | −$105M | — |
| Free cash flow margin | −95.9% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 10.1% | 9.8% |
| Last close | $1.32 | $8.72 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $79,511, sold $71,284 | — |
| Piotroski F-score | — | 2 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Century TherapeuticsSutro Biopharma
Operating margin
Percent of revenue
Century TherapeuticsSutro Biopharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Century TherapeuticsSutro Biopharma
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Century Therapeutics and Sutro Biopharma pages.